<DOC>
	<DOC>NCT02921828</DOC>
	<brief_summary>1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form of the surveillance will be completed at the time when the planned number of patients to be enrolled is reached. During a period until conditions for approval are removed, a system enabling to retrospectively collect appropriate information based on patient data from RevMate® will be, as necessary, maintained. 2. Planned duration of the surveillance Anticipated to be 2 years and 6 months from the start date of release of Pomalyst</brief_summary>
	<brief_title>A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<criteria>Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pomalyst</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>bone marrow suppression</keyword>
	<keyword>thromboembolism</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>infection</keyword>
	<keyword>tumour lysis syndrome</keyword>
	<keyword>somnolence</keyword>
	<keyword>depressed level of consciousness</keyword>
	<keyword>confusion</keyword>
	<keyword>fatigue</keyword>
	<keyword>dizziness</keyword>
	<keyword>acute renal failure</keyword>
	<keyword>heart failure</keyword>
	<keyword>arrhythmia</keyword>
	<keyword>interstitial pneumonia</keyword>
	<keyword>hypersensitivity</keyword>
	<keyword>hepatic function disorder</keyword>
	<keyword>jaundice</keyword>
</DOC>